EZH2 and lymphoma: The BCL6-overexpressing, EZH2-mutant recipients also displayed clear evidence of either lymphoma (10/12; FL or DLBCL) or pre-neoplastic lymphoid neoplasia (2/12) upon both gross pathological and histopathological inspection, while none of the mice from the other three groups (wild-type controls (0/4), EZH2-mutant only (0/4), and BCL6-overexpressing only (0/5)) showed any evidence of disease89.